146 related articles for article (PubMed ID: 28918710)
1. Trametinib for the treatment of IGHV4-34, MAP2K1-mutant variant hairy cell leukemia.
Andritsos LA; Grieselhuber NR; Anghelina M; Rogers KA; Roychowdhury S; Reeser JW; Timmers CD; Freud AG; Blachly JS; Lucas DM; Lozanski G; Jones JA; Williams K; Oakes C; Jones D; Grever MR
Leuk Lymphoma; 2018 Apr; 59(4):1008-1011. PubMed ID: 28918710
[No Abstract] [Full Text] [Related]
2. High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias.
Waterfall JJ; Arons E; Walker RL; Pineda M; Roth L; Killian JK; Abaan OD; Davis SR; Kreitman RJ; Meltzer PS
Nat Genet; 2014 Jan; 46(1):8-10. PubMed ID: 24241536
[TBL] [Abstract][Full Text] [Related]
3. Trametinib in Histiocytic Sarcoma with an Activating MAP2K1 (MEK1) Mutation.
Gounder MM; Solit DB; Tap WD
N Engl J Med; 2018 May; 378(20):1945-1947. PubMed ID: 29768143
[No Abstract] [Full Text] [Related]
4. A case of recurrent histiocytic sarcoma with MAP2K1 pathogenic variant treated with the MEK inhibitor trametinib.
Kumamoto T; Aoki Y; Sonoda T; Yamanishi M; Arakawa A; Sugiyama M; Shirakawa N; Ishimaru S; Saito Y; Maeshima A; Maeda M; Ogawa C
Int J Hematol; 2019 Feb; 109(2):228-232. PubMed ID: 30361829
[TBL] [Abstract][Full Text] [Related]
5. BRAF V600E and MAP2K1 mutations in hairy cell leukemia and splenic marginal zone lymphoma cases.
Shin SY; Lee ST; Kim HJ; Ki CS; Jung CW; Kim JW; Kim SH
Ann Lab Med; 2015 Mar; 35(2):257-9. PubMed ID: 25729732
[No Abstract] [Full Text] [Related]
6. Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation.
Xi L; Arons E; Navarro W; Calvo KR; Stetler-Stevenson M; Raffeld M; Kreitman RJ
Blood; 2012 Apr; 119(14):3330-2. PubMed ID: 22210875
[TBL] [Abstract][Full Text] [Related]
7. Clinical resistance associated with a novel MAP2K1 mutation in a patient with Langerhans cell histiocytosis.
Azorsa DO; Lee DW; Wai DH; Bista R; Patel AR; Aleem E; Henry MM; Arceci RJ
Pediatr Blood Cancer; 2018 Sep; 65(9):e27237. PubMed ID: 29768711
[TBL] [Abstract][Full Text] [Related]
8. Detection of activating MAP2K1 mutations in atypical hairy cell leukemia and hairy cell leukemia variant.
Mason EF; Brown RD; Szeto DP; Gibson CJ; Jia Y; Garcia EP; Jacobson CA; Dal Cin P; Kuo FC; Pinkus GS; Lindeman NI; Sholl LM; Aster JC; Morgan EA
Leuk Lymphoma; 2017 Jan; 58(1):233-236. PubMed ID: 27241017
[No Abstract] [Full Text] [Related]
9. Promises from trametinib in RAF active tumors.
Sausville EA
N Engl J Med; 2012 Jul; 367(2):171-2. PubMed ID: 22663012
[No Abstract] [Full Text] [Related]
10. Somatic hypermutation and VH gene usage in hairy cell leukaemia.
Arons E; Sunshine J; Suntum T; Kreitman RJ
Br J Haematol; 2006 Jun; 133(5):504-12. PubMed ID: 16681637
[TBL] [Abstract][Full Text] [Related]
11. Hairy cell leukaemia-variant: Disease features and treatment.
Matutes E; Martínez-Trillos A; Campo E
Best Pract Res Clin Haematol; 2015 Dec; 28(4):253-63. PubMed ID: 26614904
[TBL] [Abstract][Full Text] [Related]
12. V(H) gene analysis of hairy cell leukemia reveals a homogeneous mutation status and suggests its marginal zone B-cell origin.
Vanhentenrijk V; Tierens A; Wlodarska I; Verhoef G; Wolf-Peeters CD
Leukemia; 2004 Oct; 18(10):1729-32. PubMed ID: 15356640
[No Abstract] [Full Text] [Related]
13. Complete molecular remission induced by concomitant cladribine--rituximab treatment in a case of multi-resistant hairy cell leukemia.
Forconi F; Toraldo F; Sozzi E; Amato T; Raspadori D; Lauria F
Leuk Lymphoma; 2007 Dec; 48(12):2441-3. PubMed ID: 18067021
[No Abstract] [Full Text] [Related]
14. Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity?
Jain P; Ok CY; Konoplev S; Patel KP; Jorgensen J; Estrov Z; Luthra R; Kantarjian H; Ravandi F
J Clin Oncol; 2016 Mar; 34(7):e57-60. PubMed ID: 24982452
[No Abstract] [Full Text] [Related]
15. Response to Trametinib of a Pulmonary Langerhans Cell Histiocytosis Harboring a MAP2K1 Deletion.
Lorillon G; Jouenne F; Baroudjian B; de Margerie-Mellon C; Vercellino L; Meignin V; Lebbe C; Vassallo R; Mourah S; Tazi A
Am J Respir Crit Care Med; 2018 Sep; 198(5):675-678. PubMed ID: 29694792
[No Abstract] [Full Text] [Related]
16. Higher expression levels of activation-induced cytidine deaminase distinguish hairy cell leukemia from hairy cell leukemia-variant and splenic marginal zone lymphoma.
Hockley SL; Morilla A; Else M; Dearden C; Catovsky D; Morgan GJ; Matutes E; Gonzalez D
Leukemia; 2010 May; 24(5):1084-6. PubMed ID: 20237507
[No Abstract] [Full Text] [Related]
17. Expression of immunoglobulin heavy chain variable genes in B-chronic lymphocytic leukemia.
Bertin P; Risueño C; Meller C
Ann N Y Acad Sci; 1995 Sep; 764():474-7. PubMed ID: 7486569
[No Abstract] [Full Text] [Related]
18. Improved survival with MEK inhibition in BRAF-mutated melanoma.
Flaherty KT; Robert C; Hersey P; Nathan P; Garbe C; Milhem M; Demidov LV; Hassel JC; Rutkowski P; Mohr P; Dummer R; Trefzer U; Larkin JM; Utikal J; Dreno B; Nyakas M; Middleton MR; Becker JC; Casey M; Sherman LJ; Wu FS; Ouellet D; Martin AM; Patel K; Schadendorf D;
N Engl J Med; 2012 Jul; 367(2):107-14. PubMed ID: 22663011
[TBL] [Abstract][Full Text] [Related]
19. Real-time genomic profiling of histiocytoses identifies early-kinase domain BRAF alterations while improving treatment outcomes.
Lee LH; Gasilina A; Roychoudhury J; Clark J; McCormack FX; Pressey J; Grimley MS; Lorsbach R; Ali S; Bailey M; Stephens P; Ross JS; Miller VA; Nassar NN; Kumar AR
JCI Insight; 2017 Feb; 2(3):e89473. PubMed ID: 28194436
[TBL] [Abstract][Full Text] [Related]
20. Transformation of IGHV4-34+ hairy cell leukaemia-variant with U2AF1 mutation into a clonally-related high grade B-cell lymphoma responding to immunochemotherapy.
Zanelli M; Ragazzi M; Valli R; Piattoni S; Alvarez De Celis MI; Farnetti E; Orcioni GF; Longo R; Ascani S; Falini B; Tiacci E
Br J Haematol; 2016 May; 173(3):491-5. PubMed ID: 26303517
[No Abstract] [Full Text] [Related]
[Next] [New Search]
